LadRx Corporation
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumo… Read more
LadRx Corporation (LADX) - Total Liabilities
Latest total liabilities as of March 2025: $2.39 Million USD
Based on the latest financial reports, LadRx Corporation (LADX) has total liabilities worth $2.39 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LadRx Corporation - Total Liabilities Trend (2018–2024)
This chart illustrates how LadRx Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
LadRx Corporation Competitors by Total Liabilities
The table below lists competitors of LadRx Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Custodian REIT PLC
LSE:CREI
|
UK | GBX191.19 Million |
|
Magnum Goldcorp Inc
PINK:MGIDF
|
USA | $144.61K |
|
Tatton Asset Management plc
LSE:TAM
|
UK | GBX10.97 Million |
|
Daios Plastics S.A.
AT:DAIOS
|
Greece | €107.87 Million |
|
EUROPEAN MEDICAL SOLUTIONS
BR:ALEMS
|
Belgium | €41.09 Million |
|
DENNY'S
BE:DE8
|
Germany | €516.11 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down LadRx Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 9.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LadRx Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LadRx Corporation (2018–2024)
The table below shows the annual total liabilities of LadRx Corporation from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.26 Million | +2.65% |
| 2023-12-31 | $2.20 Million | -0.92% |
| 2022-12-31 | $2.22 Million | -43.78% |
| 2021-12-31 | $3.95 Million | +23.86% |
| 2020-12-31 | $3.19 Million | +55.55% |
| 2019-12-31 | $2.05 Million | -20.02% |
| 2018-12-31 | $2.56 Million | -- |